BC Extra | Apr 18, 2017
Company News

Alpine finds public path through Nivalis

Immunology company Alpine Immune Sciences Inc. (Seattle, Wash.) and cystic fibrosis play Nivalis Therapeutics Inc. (NASDAQ:NVLS) said they will merge in an all-stock transaction. Upon the deal's close, expected in 3Q17, the combined company will...
BC Week In Review | Mar 17, 2017
Clinical News

Cavosonstat: Ph II SNO-7 data

Top-line data from the double-blind, U.S. Phase II SNO-7 trial in 19 adult CF patients who had 1 copy of the F508del mutation in the CF transmembrane conductance regulatory (CFTR) gene and a second mutation...
BC Week In Review | Jan 27, 2017
Company News

Nivalis restructuring

Nivalis will reduce headcount by 25 (83%) to about 5 to preserve cash while exploring strategic alternatives, including an acquisiton and merger. The headcount reduction will include President and CEO Jon Congleton, CMO and EVP...
BC Week In Review | Dec 14, 2016
Clinical News

Cavosonstat: Ph II data

Top-line data from a double-blind, U.S. Phase II trial in 138 CF patients with 2 copies of the F508del mutation in the CF transmembrane conductance regulatory (CFTR) gene showed that twice-daily 200 and 400 mg...
BC Week In Review | Nov 22, 2016
Clinical News

Cavosonstat: Completed Ph II enrollment

Nivalis completed enrollment of 19 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 400 mg oral N91115 twice daily for 12 weeks plus Kalydeco ivacaftor. The trial enrolled adult CF patients with 1...
BC Week In Review | Jul 18, 2016
Clinical News

Cavosonstat: Completed Phase II enrollment

Nivalis completed enrollment of 138 patients who have 2 copies of the F508del mutation in the CF transmembrane conductance regulatory ( CFTR ) gene in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 200 and 400 mg...
BC Week In Review | May 23, 2016
Clinical News

N91115: Phase II started

Nivalis began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 400 mg oral N91115 twice daily for 12 weeks plus Kalydeco ivacaftor in about 20 patients. The trial is enrolling adult CF patients with...
BC Week In Review | Mar 14, 2016
Clinical News

N91115: Phase II ongoing

Nivalis said an IDMC recommended continuation of a double-blind, placebo-controlled, U.S. Phase II trial of oral N91115 based on interim safety data on the lower dose. The trial is evaluating 200 and 400 mg N91115...
BC Week In Review | Dec 14, 2015
Clinical News

N91115: Phase II started

Nivalis began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 200 and 400 mg oral N91115 twice daily with oral Orkambi lumacaftor/ivacaftor in 135 CF patients who have 2 copies of the F508del mutation...
BC Week In Review | Oct 19, 2015
Clinical News

N91115: Phase Ib data

Top-line data from a double-blind, U.S. Phase Ib trial in 51 CF patients with 2 copies of the delta F508 CF transmembrane conductance regulator ( CFTR ) mutation showed that twice-daily 50, 100 and 200 mg doses...
Items per page:
1 - 10 of 14